

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60401	INTERNATIONAL APPLICATION NO. PCT/US2004/022946
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Gardner, et al.	
		INT FILING DATE 16 July 2004	GROUP

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes   No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	SMYTHE, M.A., et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. American Journal of Hematology, 2002, Vol. 71, pages 50-52, especially p. 52.
	KONDO, L.M., et al. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Annals of Pharmacotherapy, April 2001, Vol. 35, pages 440-451, especially pages 442 and 446.
	ADKINS, J.C. et al. Lepirudin: a review of its potential place in the management of thrombotic disorders. BioDrugs. Sept. 1998, Vol. 10, No.3 pages 227-255, especially p. 228, 232-233, 239-241, 247, and 249-251.
	LAPOSATA, M.L., et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban. Archives of Pathology and Laboratory Medicine. September 1998, Vol. 122, No. 9, pages 799-807, especially pages 801 and 804-805.
	HURSTING, M.J. et al. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clinical Chemistry. 1999, Vol. 45, No. 3, pages 409-412, especially p. 411.
no copies of lined-through references provided with application	
EXAMINER /Lora E Barnhart/	DATE CONSIDERED 12/23/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

n:\soma\cases\pu60399\plus national transmittal.doc

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /leb/